Forbes J M & Co. LLP Invests $1.02 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Forbes J M & Co. LLP bought a new stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 125,000 shares of the company's stock, valued at approximately $1,019,000. Forbes J M & Co. LLP owned 0.22% of Ginkgo Bioworks as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Paloma Partners Management Co acquired a new position in Ginkgo Bioworks during the first quarter worth $28,000. First Trust Direct Indexing L.P. purchased a new stake in shares of Ginkgo Bioworks in the first quarter valued at about $35,000. Russell Investments Group Ltd. raised its holdings in shares of Ginkgo Bioworks by 9,440.6% in the first quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company's stock valued at $37,000 after purchasing an additional 31,626 shares during the last quarter. Smith Salley Wealth Management raised its holdings in shares of Ginkgo Bioworks by 125.0% in the first quarter. Smith Salley Wealth Management now owns 54,000 shares of the company's stock valued at $63,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Ginkgo Bioworks in the second quarter valued at about $36,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Analyst Upgrades and Downgrades

DNA has been the subject of several analyst reports. TD Cowen increased their target price on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a "buy" rating in a report on Friday, September 20th. BTIG Research increased their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the company a "sell" rating in a research report on Friday, August 23rd. Finally, The Goldman Sachs Group reduced their price target on shares of Ginkgo Bioworks from $0.80 to $0.30 and set a "sell" rating for the company in a research report on Tuesday, July 9th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Ginkgo Bioworks currently has a consensus rating of "Hold" and an average target price of $4.16.

Ginkgo Bioworks Trading Up 1.3 %

Shares of DNA traded up $0.11 during trading hours on Monday, hitting $8.27. The company's stock had a trading volume of 576,188 shares, compared to its average volume of 1,143,592. The company has a market cap of $459.65 million, a P/E ratio of -0.45 and a beta of 1.10. The company has a 50 day moving average price of $7.51. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.26 and a 52-week high of $75.20.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($3.20) EPS for the quarter, meeting the consensus estimate of ($3.20). The company had revenue of $56.21 million during the quarter, compared to analysts' expectations of $41.46 million. Ginkgo Bioworks had a negative net margin of 486.98% and a negative return on equity of 63.09%. As a group, sell-side analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -12.6 EPS for the current year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.